DOCSLIB.ORG

Serotonin Syndrome in Asymptomatic Huntington's Disease

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Serotonin Syndrome in Asymptomatic Huntington's Disease Serotonin syndrome I Case notes Serotonin syndrome in asymptomatic Huntington’s disease Verity Haffenden BSc, MBBS, Anish Patel MBChB, MRCPsych, MedEd(Cert) Serotonin syndrome is a rare Figure 1. Hunter’s Criteria (adapted from Boyer and Shannon, 2005)6 and serious condition most often resulting from iatrogenic insult; the prescriber’s pen is Has a serotonergic agent been administered in the past five weeks? sometimes the most poisonous. Here, Dr Haffenden and Dr No Yes Patel discuss a complex case of serotonin syndrome in a patient with genetically proven, but not Not serotonin Are any of the following symptoms yet symptomatic, Huntington’s syndrome present? disease and chronic renal Tremor and hyperreflexia impairment. A screening Spontaneous clonus process is proposed to recognise the multitude of No Muscle rigidity, temperature >38°C, and Yes precipitating factors, which either ocular clonus or inducible clonus aligned in this case, and could Ocular clonus and either agitation or either alter our prescribing or diaphoresis expedite recognition. Inducible clonus and either agitation or diaphoresis untington’s disease (HD), a Hprogressive neurodegenerative Not serotonin Serotonin disease, is clinically diagnosed with syndrome syndrome a triad of signs/symptoms: chorea; psychiatric illness, and dementia. Research has shown neurotransmit- surgery was performed using a Past medical history of note ter deficits in mice models of Hun- cadaveric specimen but his postoper- included a genetic, but not yet tington’s1 both before and after ative period was complicated by anti- symptomatic, diagnosis of HD and symptomatic disease presence2 – body-mediated rejection and past psychiatric history included namely a reduction in serotonin. A steroid-induced psychosis (resolved depression, for which he was taking review of the research demon- with reduction of steroids and admin- citalopram 20mg once daily. The strated a few cases of neuroleptic istration of PRN haloperidol). Six only other prescribed medication malignant syndrome (NMS)3 but weeks postoperatively the patient was with a psychotropic effect was tram- found no linked cases of serotonin improving and his creatinine had adol, prescribed for analgesia. syndrome (SS) and either sympto- fallen from 1006µmol to 368µmol Assessment and examination matic or asymptomatic HD. As such but he became acutely confused and revealed a diaphoresis, bilateral our patient sparked a lot of multi- was wandering the ward naked, trem- inducible clonus and hyperreflexia, disciplinary interest. ulous and clammy. Investigations, upper limb tremor and expressive including bloods, CT head and lum- dysphasia. Approximately 30 min- Case presentation bar puncture, did not uncover the utes prior to this episode the patient A 53-year-old male was admitted for aetiology and he was referred to our had received a stat dose of the renal transplant, due to renal failure liaison psychiatry service for assess- antiemetic ondansetron, 4mg intra- resulting from an IgA nephropathy, ment and diagnosis of this acute venous, as he was feeling nauseated. with a creatinine of 1006µmol/L. His alteration in his mental state. Blood tests revealed a chronic renal www.progressnp.com Progress in Neurology and Psychiatry I Vol. 22 Iss. 1 2018 I 21 Case notes I Serotonin syndrome impairment, hyperkalaemia, hyper- serotonin syndrome in patients with medication thus potentially pre- calcaemia, anaemia, raised lactate a previous psychiatric history who cipitating serotonin syndrome. and mild leucocytosis. were given ondansetron, linked to Our patient was taking citalo- With consideration of the symp- the concomitant use of pro-seroton- pram and given a stat dose of toms and use of three drugs with a ergic medications, but again high- ondansetron. Both of these med- serotonergic action model (citalo- lighting the role of ondansetron in ications work with CYP450 in pram, tramadol and ondansetron) patients who are predisposed to neu- some way; ondansetron is a sub- a working diagnosis of serotonin rotransmitter deficit.8 strate for the CYP1A2 enzyme, syndrome was made. Management We feel our case highlights the which is inhibited by citalo- was supportive with cessation of ser- combination of several predispos- pram.10 This interaction results in otonergic agents and IV hydration, ing factors making this patient accumulation of ondansetron. and complete recovery was seen more vulnerable to the use of mul- after approximately 48 hours. tiple serotonergic agents. These This complex interplay also empha- include: sises the desirability of a medication Discussion • Factors affecting renal clearance – interaction checking tool to aid safe This case highlights an example of ser- Reduced renal clearance leads to prescribing. With knowledge of otonin syndrome, a condition result- higher circulating plasma concen- these enzymes and the emerging ing in a number of symptoms, trations of serotonin. With a use of mechanistic models in pre- including hyperthermia, clonus, dia- chronic renal impairment it is likely dicting drug-drug interactions we phoresis, agitation and hyperreflexia. our patient was not able to clear ser- may in the future be able to predict An increased serum serotonin level otonin as one would expect. severe adverse reactions in specific does not predict the development of • Neurodegenerative conditions – There patient populations.11 serotonin syndrome and cannot be is evidence in the literature to suggest used to aid diagnosis.4 A useful and that patients with a neurodegenera- Implications for clinical care accurate diagnostic tool in these tive condition such as Parkinson’s dis- Our case not only adds to the litera- patients is Hunter’s criteria5 as out- ease are predisposed to the ture a previously unpublished case lined in Figure 1;6 with a sensitivity of development of serotonin syndrome.9 of serotonin syndrome associated 84% and a specificity of 97% this is Perhaps an already vulnerable brain is with HD. It also usefully illustrates now the accepted standard reference more easily influenced by small multiple predisposing and precipi- tool for diagnosis. Treatment of sero- changes in neurotransmitters. We pos- tating factors occurring together, tonin syndrome is conservative and tulate that the same is the case with that have been previously implicated supportive with discontinuation of ser- HD; although no reported cases were individually, in the development of otonergic agents, active cooling mech- found on review of the literature, we serotonin syndrome. Dissecting out anisms for hyperthermia, airway and were able to find evidence of cases these factors in an attempt to dis- volume support and benzodiazepines associating the equally lethal condi- cover why our patient developed ser- for agitation.4 This patient’s presenta- tion of NMS in four patients with HD.3 otonin syndrome helps to formulate tion met the suggested diagnostic cri- Although a different neurotransmit- a checklist that can prompt clini- teria for serotonin syndrome given the ter is implicated in the development cians to consider their prescribing acute onset of neuropsychiatric symp- of NMS, perhaps an association decisions. In the age of electronic toms and resolution of symptoms between the syndrome and a neurode- prescribing this could be an auto- upon cessation of serotonergic agents generative condition demonstrates an mated algorithm that produces an in the absence of any alternative element of vulnerability to subtle alert with the prescription of two or medical aetiology. changes in neurotransmitter levels. more serotonergic drugs with Although some of the literature • Pharmacokinetics – Certain increasing severity dependent on refutes the role of ondansetron in cytochrome P450 (CYP450) the patient’s creatinine, neurologi- the development of serotonin syn- enzymes have been implicated in cal vulnerability and psychiatric his- drome7 a clear temporal association the development of serotonin tory. Frequent prompting in this between ondansetron treatment and syndrome. These enzymes metab- manner would also increase aware- onset of serotonin toxicity is demon- olise multiple drugs and can also ness of serotonin syndrome amongst strated here in a neurologically vul- be inhibited by multiple drugs; prescribers and thus potentially nerable patient. There have been their inhibition may result in the expedite diagnosis and subsequent case reports of the development of accumulation of a serotonergic cessation of serotonergic agents. 22 I Progress in Neurology and Psychiatry I Vol. 22 Iss. 1 2018 www.progressnp.com Serotonin syndrome I Case notes Conclusion Liaison Psychiatrist, both at NBT 5. Dunkley EJ, Isbister GK, Sibbritt D, et al. The This case raises several points that Mental Health Liaison Team, South- Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin are of clinical importance. Firstly, it mead Hospital, Bristol. toxicity. QJM 2003;96(9):635–42. acts as a reminder of the serious 6. Boyer EW, Shannon M. The serotonin and potentially fatal serotonin syn- Declaration of interests syndrome. N Engl J Med 2005;352(11):1112–20. 7. Rojas-Fernandez CH. Can 5-HT3 Antagonists drome. Secondly, it highlights the No conflicts of interest were Really Contribute to Serotonin Toxicity? A Call need for adequate risk assessment declared. for Clarity and Pharmacological Law and Order. Drugs Real World Outcomes 2014;1(1):3–5. prior to the prescription of a sero- 8. Schuch LG, Yip A, Nouri KF, et al. Serotonin tonergic
Load more

Recommended publications
  • Canadian Stroke Best Practice Recommendations
    CANADIAN STROKE BEST PRACTICE RECOMMENDATIONS MOOD, COGNITION AND FATIGUE FOLLOWING STROKE Table 1C: Summary Table for Selected Pharmacotherapy for Post-Stroke Depression Update 2019 Lanctôt KL, Swartz RH (Writing Group Chairs) on Behalf of the Canadian Stroke Best Practice Recommendations Mood, Cognition and Fatigue following Stroke Writing Group and the Canadian Stroke Best Practice and Quality Advisory Committee, in collaboration with the Canadian Stroke Consortium © 2019 Heart & Stroke Heart and Stroke Foundation Mood, Cognition and Fatigue following Stroke Canadian Stroke Best Practice Recommendations Table 1C Table 1C: Summary Table for Selected Pharmacotherapy for Post-Stroke Depression This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on selected classes of medications available for use in Canada and more commonly recommended for post-stroke depression. This table should be used as a reference guide by health care professionals when selecting an appropriate agent for individual patients. Patient compliance, patient preference and/or past experience, side effects, and drug interactions should all be taken into consideration during decision-making, in addition to other information provided in this table and available elsewhere regarding these medications. Selective Serotonin Reuptake Inhibitors (SSRI) Serotonin–norepinephrine reuptake Other inhibitors (SNRI) Medication *citalopram – Celexa *duloxetine – Cymbalta methylphenidate – Ritalin (amphetamine)
    [Show full text]
  • Monoamine Oxydases Et Athérosclérose : Signalisation Mitogène Et Études in Vivo
    UNIVERSITE TOULOUSE III - PAUL SABATIER Sciences THESE Pour obtenir le grade de DOCTEUR DE L’UNIVERSITE TOULOUSE III Discipline : Innovation Pharmacologique Présentée et soutenue par : Christelle Coatrieux le 08 octobre 2007 Monoamine oxydases et athérosclérose : signalisation mitogène et études in vivo Jury Monsieur Luc Rochette Rapporteur Professeur, Université de Bourgogne, Dijon Monsieur Ramaroson Andriantsitohaina Rapporteur Directeur de Recherche, INSERM, Angers Monsieur Philippe Valet Président Professeur, Université Paul Sabatier, Toulouse III Madame Nathalie Augé Examinateur Chargé de Recherche, INSERM Monsieur Angelo Parini Directeur de Thèse Professeur, Université Paul Sabatier, Toulouse III INSERM, U858, équipes 6/10, Institut Louis Bugnard, CHU Rangueil, Toulouse Résumé Les espèces réactives de l’oxygène (EROs) sont impliquées dans l’activation de nombreuses voies de signalisation cellulaires, conduisant à différentes réponses comme la prolifération. Les EROs, à cause du stress oxydant qu’elles génèrent, sont impliquées dans de nombreuses pathologies, notamment l’athérosclérose. Les monoamine oxydases (MAOs) sont deux flavoenzymes responsables de la dégradation des catécholamines et des amines biogènes comme la sérotonine ; elles sont une source importante d’EROs. Il a été montré qu’elles peuvent être impliquées dans la prolifération cellulaire ou l’apoptose du fait du stress oxydant qu’elles génèrent. Ce travail de thèse a montré que la MAO-A, en dégradant son substrat (sérotonine ou tyramine), active une voie de signalisation mitogène particulière : la voie métalloprotéase- 2/sphingolipides (MMP2/sphingolipides), et contribue à la prolifération de cellules musculaire lisses vasculaires induite par ces monoamines. De plus, une étude complémentaire a confirmé l’importance des EROs comme stimulus mitogène (utilisation de peroxyde d’hydrogène exogène), et a décrit plus spécifiquement les étapes en amont de l’activation de MMP2, ainsi que l’activation par la MMP2 de la sphingomyélinase neutre (première enzyme de la cascade des sphingolipides).
    [Show full text]
  • Targeting the Tryptophan Hydroxylase 2 Gene for Functional Analysis in Mice and Serotonergic Differentiation of Embryonic Stem Cells
    TARGETING THE TRYPTOPHAN HYDROXYLASE 2 GENE FOR FUNCTIONAL ANALYSIS IN MICE AND SEROTONERGIC DIFFERENTIATION OF EMBRYONIC STEM CELLS Inaugural-Dissertation to obtain the academic degree Doctor rerum naturalium (Dr. rer. nat.) submitted to the Department of Biology, Chemistry and Pharmacy of Freie Universität Berlin by Dana Kikic, M.Sc. in Molecular biology and Physiology from Nis June, 2009 The doctorate studies were performed in the research group of Prof. Michael Bader Molecular Biology of Peptide Hormones at Max-Delbrück-Center for Molecular Medicine in Berlin, Buch Mai 2005 - September 2008. 1st Reviewer: Prof. Michael Bader 2nd Reviewer: Prof. Udo Heinemann date of defence: 13. August 2009 ACKNOWLEDGMENTS Herewith, I would like to acknowledge the persons who made this thesis possible and without whom my initiation in the world of basic science research would not have the spin it has now, neither would my scientific illiteracy get the chance to eradicate. I am expressing my very personal gratitude and recognition to: Prof. Michael Bader, for an inexhaustible guidance in all the matters arising during the course of scientific work, for an instinct in defining and following the intellectual challenge and for letting me following my own, for necessary financial support, for defining the borders of reasonable and unreasonable, for an invaluable time and patience, and an amazing efficiency in supporting, motivating, reading, correcting and shaping my scientific language during the last four years. Prof. Harald Saumweber and Prof. Udo Heinemann, for taking over the academic supervision of the thesis, and for breathing in it a life outside the laboratory walls and their personal signature.
    [Show full text]
  • The Pharma-Fever That Almost Got Away
    EMERGENCY MEDICINE RESIDENCY CPC The pharma-fever that almost got away XIAO CHI ZHANG, MD, MS; MATTHEW SIKET, MD; WILLIAM BINDER, MD 29 31 EN From the Case Records of the Alpert Medical School of DR. SARAH GAINES: A fever greater than 41.0°C is quite Brown University Residency in Emergency Medicine elevated and unusual. Is this dangerous? What was your differential? DR. XIAO CHI ZHANG: A 68-year-old man was brought into DR. MATTHEW SIKET: Humans generally tolerate tempera- the Emergency Department by his family with chills and tures below 41° C (105.8° F). In contrast to hyperthermia, in altered mental status. Two days prior to his ED presenta- which an imbalance between heat generation versus dissipa- tion, the patient had an episode in which he “spaced-out” tion occurs without up-regulation of the hypothalamic set and was unable to comprehend or acknowledge his wife. She point, fever as a host defense against infection rarely reaches reported that he did not have any signs of seizure activity dangerous levels in neurologically competent individuals. and did not have any focal weakness. The episode lasted Very high temperatures can be related to urosepsis, intraab- approximately 30 minutes and he returned to his baseline. dominal sepsis, C. difficile colitis, meningitis, and central Today he had another episode, but this time associated with venous catheter infections. Hyperpyrexia, defined as tem- chills and rigors. His past medical history was significant perature > 41.5°C (106.7°F) is an uncommon result of infec- for chronic back pain due to bony metastasis from Stage IV tion and usually implies central fever, neurologic malignant non-small cell lung adenocarcinoma, requiring palliative syndrome, malignant hyperthermia, adrenal insufficiency, gamma knife radiation, as well as a daily oral chemotherapy or a drug related cause.1 Our patient was hyperpyrexic, sug- agent, erlotinib, an oral tyrosine kinase inhibitor.
    [Show full text]
  • The Neurochemical Consequences of Aromatic L-Amino Acid Decarboxylase Deficiency
    The neurochemical consequences of aromatic L-amino acid decarboxylase deficiency Submitted By: George Francis Gray Allen Department of Molecular Neuroscience UCL Institute of Neurology Queen Square, London Submitted November 2010 Funded by the AADC Research Trust, UK Thesis submitted for the degree of Doctor of Philosophy, University College London (UCL) 1 I, George Allen confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. Signed………………………………………………….Date…………………………… 2 Abstract Aromatic L-amino acid decarboxylase (AADC) catalyses the conversion of 5- hydroxytryptophan (5-HTP) and L-3,4-dihydroxyphenylalanine (L-dopa) to the neurotransmitters serotonin and dopamine respectively. The inherited disorder AADC deficiency leads to a severe deficit of serotonin and dopamine as well as an accumulation of 5-HTP and L-dopa. This thesis investigated the potential role of 5- HTP/L-dopa accumulation in the pathogenesis of AADC deficiency. Treatment of human neuroblastoma cells with L-dopa or dopamine was found to increase intracellular levels of the antioxidant reduced glutathione (GSH). However inhibiting AADC prevented the GSH increase induced by L-dopa. Furthermore dopamine but not L-dopa, increased GSH release from human astrocytoma cells, which do not express AADC activity. GSH release is the first stage of GSH trafficking from astrocytes to neurons. This data indicates dopamine may play a role in controlling brain GSH levels and consequently antioxidant status. The inability of L-dopa to influence GSH concentrations in the absence of AADC or with AADC inhibited indicates GSH trafficking/metabolism may be compromised in AADC deficiency.
    [Show full text]
  • PRESCRIBED DRUGS and NEUROLOGICAL COMPLICATIONS K a Grosset, D G Grosset Iii2
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.2004.045757 on 16 August 2004. Downloaded from PRESCRIBED DRUGS AND NEUROLOGICAL COMPLICATIONS K A Grosset, D G Grosset iii2 J Neurol Neurosurg Psychiatry 2004;75(Suppl III):iii2–iii8. doi: 10.1136/jnnp.2004.045757 treatment history is a fundamental part of the healthcare consultation. Current drugs (prescribed, over the counter, herbal remedies, drugs of misuse) and how they are taken A(frequency, timing, missed and extra doses), drugs tried previously and reason for discontinuation, treatment response, adverse effects, allergies, and intolerances should be taken into account. Recent immunisations may also be of importance. This article examines the particular relevance of medication in patients presenting with neurological symptoms. Drugs and their interactions may contribute in part or fully to the neurological syndrome, and treatment response may assist diagnostically or in future management plans. Knowledge of medicine taking behaviour may clarify clinical presentations such as analgesic overuse causing chronic daily headache, or severe dyskinesia resulting from obsessive use of dopamine replacement treatment. In most cases, iatrogenic symptoms are best managed by withdrawal of the offending drug. Indirect mechanisms whereby drugs could cause neurological problems are beyond the scope of the current article—for example, drugs which raise blood pressure or which worsen glycaemic control and consequently increase the risk of cerebrovascular disease, or immunosupressants
    [Show full text]
  • Gastric Serotonin Biosynthesis and Its Functional Role in L-Arginine-Induced Gastric Proton Secretion
    International Journal of Molecular Sciences Article Gastric Serotonin Biosynthesis and Its Functional Role in L-Arginine-Induced Gastric Proton Secretion Ann-Katrin Holik 1,†, Kerstin Schweiger 1,†, Verena Stoeger 2, Barbara Lieder 1,2 , Angelika Reiner 3, Muhammet Zopun 1, Julia K. Hoi 2, Nicole Kretschy 4, Mark M. Somoza 4,5,6 , Stephan Kriwanek 7, Marc Pignitter 1 and Veronika Somoza 1,2,6,8,* 1 Department of Physiological Chemistry, Faculty of Chemistry, University of Vienna, Althanstraße 14, 1090 Vienna, Austria; [email protected] (A.-K.H.); [email protected] (K.S.); [email protected] (B.L.); [email protected] (M.Z.); [email protected] (M.P.) 2 Christian Doppler Laboratory for Bioactive Aroma Compounds, Faculty of Chemistry, University of Vienna, Althanstraße 14, 1090 Vienna, Austria; [email protected] (V.S.); [email protected] (J.K.H.) 3 Pathologisch-Bakteriologisches Institut, Sozialmedizinisches Zentrum Ost- Donauspital, Langobardenstraße 122, 1220 Vienna, Austria; [email protected] 4 Department of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Althanstraße 14, 1090 Vienna, Austria; [email protected] (N.K.); [email protected] (M.M.S.) 5 Food Chemistry and Molecular Sensory Science, Technical University of Munich, Lise-Meitner-Straße 34, 85354 Freising, Germany 6 Leibniz Institute for Food Systems Biology, Technical University of Munich, Lise-Meitner-Str. 34, 85345 Freising, Germany 7 Chirurgische Abteilung, Sozialmedizinisches Zentrum Ost- Donauspital, Langobardenstraße 122, Citation: Holik, A.-K.; Schweiger, K.; 1220 Vienna, Austria; [email protected] 8 Stoeger, V.; Lieder, B.; Reiner, A.; Nutritional Systems Biology, School of Life Sciences, Technical University of Munich, Lise-Meitner-Str.
    [Show full text]
  • Catatonia, NMS, and Serotonin Syndrome
    Catatonia, NMS, and Serotonin Syndrome Christopher M. Celano, MD, FACLP Associate Director, Cardiac Psychiatry Research Program, Massachusetts General Hospital Assistant Professor of Psychiatry, Harvard Medical School October 22, 2020 www.mghcme.org Disclosure: Christopher Celano, MD Sunovion Company Pharmaceuticals Employment Management Independent Contractor Consulting Speaking & Teaching I Board, Panel or Committee Membership D – Relationship is considered directly relevant to the presentation I – Relationship is NOT considered directly relevant to the presentation www.mghcme.org Catatonia: How common is it? • 7.8-9.0% prevalence rate – Highest rates in non-psychiatric (i.e., medical) settings and in patients undergoing ECT. • 1.6-5.5% of all patients seen on psychiatry consultation service – Prevalence higher for older patients • Up to 46% of cases may have etiology that is not primarily psychiatric Grover 2015, Carroll 1994, Jaimes-Albornoz 2013, Fricchione 2008 www.mghcme.org When are you called? • Staff reports the patient is “Playing POSSUM” • Perseveration (speech or behavior) • Oppositionality to all requests • Speech that trails off or is whispereD • Slowed response to questions or commands • Undernourished (reports of decreased PO intake) • Motionless but awake www.mghcme.org Diagnosing Catatonia: DSM-5 DSM-5 requires 3 or more of the following: • Catalepsy • Posturing • Waxy flexibility • Mannerisms • Stupor • Stereotypies • Agitation • Grimacing • Mutism • Echolalia • Negativism • Echopraxia American Psychiatric Association 2013 www.mghcme.org Bush-Francis Rating Scale • Excitement • VerBigeration • Immobility/stupor • Rigidity • ComBativeness • Negativism • Autonomic Abnormality • Waxy flexiBility • Impulsivity • Withdrawal • Mutism • Automatic OBedience • Staring • Mitgehen • Posturing/catalepsy • Gegenhalten • Grimacing • AmBitendency • Echopraxia/echolalia • Grasp Reflex • Stereotypy • Perseveration • Mannerisms Bush 1996 www.mghcme.org Challenges with Diagnosis • Clarifying specific symptoms can be difficult – Rigidity vs.
    [Show full text]
  • Triptan Therapy for Acute Migraine
    Triptan Therapy for Acute Migraine Headache John Farr Rothrock, MD University of Alabama at Birmingham, Birmingham, AL Deborah I. Friedman, MD, MPH University of Texas Southwestern, Dallas, TX The “triptans” are 5HT-1B/1D receptor agonists that were developed to treat acute migraine and acute cluster headache. Sumatriptan, the original triptan preparation, has been in general use since 1993, so there has been considerable experience with triptans over time. There are currently seven oral triptans on the market in the United States: sumatriptan (Imitrex™), naratriptan (Amerge™), zolmitriptan (Zomig™), rizatriptan (Maxalt™), almotriptan (Axert™), frovatriptan (Frova™), and eletriptan (Relpax™); brand names may differ by country. There is also a combination preparation of oral sumatriptan/naproxen (Treximet™). Two triptans (sumatriptan, zolmitriptan) are marketed as nasal sprays, and sumatriptan is available for subcutaneous injection, including a needle-free subcutaneous delivery system (Sumavel™). Sumatriptan suppositories are marketed in Europe but not in North America. Zolmitriptan and rizatriptan are sold in an oral disintegrating tablet or “melt” formulation as well as in tablet form; while the “melt” formulations may be more convenient (no liquid is required to propel them into the stomach), they are absorbed similarly to regular tablets and there is no evidence to suggest that they work faster than the tablet formulations. Some patients with migraine-associated nausea prefer the disintegrating tablets while others cannot tolerate their taste. Although all of the triptans initially were investigated for the treatment of migraine headache of moderate to severe intensity and were superior to placebo in those pivotal trials, they appear to be more consistently effective when used to treat migraine earlier in the attack, when the headache is still mild to moderate.
    [Show full text]
  • Neuroleptic Malignant Syndrome Vs Serotonin Syndrome: Can They Be Distinguished Without an Underlying Etiology?
    Neuroleptic Malignant Syndrome vs Serotonin Syndrome: Can They Be Distinguished Without an Underlying Etiology? Roy R. Reeves, DO, PhD; Mark E. Ladner, MD; and Percy Smith, PA The potentially serious complications for patients with neuroleptic malignant syndrome and serotonin syndrome cannot be underplayed by mental health clinicians, patients, and their families. The authors discuss clinical similarities and diagnostic and treatment approaches to the 2 syndromes. euroleptic malignant syn- of symptoms or whether the patient ployment. He had stopped taking his drome (NMS) and sero- was taking different medications that medication (risperidone 3-mg daily) tonin syndrome (SS) are rare could affect both the serotonin and 3 months earlier, because he was Nbut potentially fatal condi- dopamine systems. experiencing adverse effects (AEs) tions associated with the treatment In clinical practice many patients and shortly thereafter hearing voices. of psychotropic medications. Neu- are treated concurrently with both The clinic psychiatrist started him on roleptic malignant syndrome is be- dopamine receptor antagonists and olanzapine 10-mg daily and sertra- lieved to be caused by a reduction in agents that increase serotonin activity. line 50-mg daily. At a follow-up visit dopaminergic activity secondary to Thus, the distinction of NMS and SS a week later, Mr. A showed an im- drug-induced dopaminergic block- may be problematic if these patients provement of his mood and reported age, whereas SS results from an ex- develop symptoms that could be at- that his hallucinations had decreased cess of central nervous system (CNS) tributed to either disorder. This article significantly. serotonin activity, usually because will discuss the clinical similarities of Several days later, Mr.
    [Show full text]
  • JAMA Neurology Pages 525-636
    In This Issue May 2018 Volume 75, Number 5 JAMA Neurology Pages 525-636 Research Opinion Amyloid and Tau Accumulation in Young Adults With ADAD 548 Viewpoint 531 Preventing Sudden Unexpected Although the medial temporal lobe is typically the first area of neurofibrillary tangle depo- Death in Epilepsy sition in aging populations, it is not clear if this is the case for younger individuals who are O Devinsky and Coauthors predisposed to autosomal dominant Alzheimer disease (ADAD). In a cross-sectional study, Quiroz and coauthors used positron emission tomography imaging to measure amyloid and Clinical Review & Education tau deposition in 24 participants (mean [SD] age, 38.0 [7.4] years) from a large Colombian Review kindred with ADAD. The authors report that amyloid accumulates in the cortex of unim- paired presenilin 1 E280A mutation carriers 10 to 15 years before symptom onset, whereas tau deposits emerge in the medial temporal lobe approximately 6 years before and then spread into the cortex as carriers move closer to clinical onset. These findings suggest that amyloid prompts the spread of tau pathology beyond the medial temporal lobe and that the presence of tau is closely associated with memory decline. Editorial perspective is pro- vided by McDade and Bateman. Editorial 536 Risk of Serotonin Syndrome With Triptans and Antidepressants 566 In 2006, the US Food and Drug Administration issued a warning regarding the potential risk of serotonin syndrome with coprescription of triptan antimigraine drugs and selective sero- 620 Review of the Neurological toninreuptakeinhibitororselectivenorepinephrinereuptakeinhibitorantidepressantsbased Implications of von Hippel–Lindau Disease D Dornbos III and Coauthors on a small number of case reports.
    [Show full text]
  • Catatonia, Serotonin Syndrome and Parkinsonism
    MJP Online Early 01-01-17 CASE REPORT A Diagnostic Dilemma: Catatonia, Serotonin Syndrome and Parkinsonism Mohd Miharbei MF1,2, Ahmad Zafri AB1, Suhaila MZ1 1Jabatan Psikiatri dan Kesihatan Mental, Hospital Tengku Ampuan Afzan, 25100 Kuantan, Pahang, Malaysia 2Department of Psychological Medicine, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia Abstract Catatonia may concomitantly occur with other psychiatric diagnoses such as Major Depressive Disorder, however problem in diagnosis may arise due to the overlapping features with other problems such as serotonin syndromes, neuroleptic malignant syndromes and Parkinsonism. Despite the diagnostic dilemma and lack of diagnostic tools, the clinical correlation between the carbon monoxide poisoning and the late-onset development of the Parkinsonian features is the highlight of this report. Keywords: Catatonia, Parkinsonism, Carbon Monoxide Poisoning Introduction symptoms such as stuporous nature of the patient, rigidity, tremor and bradykinesia. Catatonic syndromes are a diagnostic conundrum and always offer a therapeutic Despite the similarity, the option and challenge as well. Catatonia is an associated response towards treatment are quite feature in major psychiatric diagnoses, as different. While electroconvulsive therapy is well as a prominent overlapping features in a known treatment option in catatonic state, neuroleptic malignant syndrome, akinetic it may not be the case for the state of parkinsonism and representing motor serotonergic syndrome and Parkinsonism. features of serotonergic syndromes [1,3]. The list of the possible cause of similar Case report presentations are vast. Among others, carbon monoxide poisoning is known to Mr LHC, a 58 years old Chinese male, with cause delayed onset Parkinsonism [2]. background history of methamphetamine abuse, presented to the hospital following Among the said differentials, there are few unconsciousness episode at home.
    [Show full text]